This trial is conducted in Europe. The aim of this clinical trial is to compare the blood glucose lowering effect of NN5401(insulin degludec/insulin aspart (IDegAsp)) with NN1250 (insulin degludec (IDeg)) and insulin aspart (IAsp) in subjects with type 1 diabetes where the trial participant will receive one single dose of each trial product in varying order.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
27
Insulin degludec single-dose of 0.5 U/kg body weight injected subcutaneously (under the skin).
Insulin degludec/insulin aspart single-dose of 0.5 U/kg body weight injected subcutaneously (under the skin).
Insulin aspart single-dose of 0.5 U/kg body weight injected subcutaneously (under the skin).
Unnamed facility
Neuss, Germany
Area under the glucose infusion rate curve
Time frame: From 0 to 6 hours after single-dose administration
Area under the glucose infusion rate curve
Time frame: From 4 to 24 hours after single-dose administration
Area under the insulin degludec concentration-time curve
Time frame: From 0 to 120 hours after single-dose administration
Maximum observed insulin degludec concentration
Time frame: From 0 to 120 hours after single-dose administration
Area under the insulin aspart concentration-time curve
Time frame: From 0 to 12 hours after single-dose administration
Maximum observed insulin aspart concentration
Time frame: 0-12 hours after single-dose administration
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.